1
|
William J Britt |
University of Alabama, Birmingham, USA |
Pathogenesis of perinatal / congenital CMV infection of CNS
|
2
|
Hans Dieplinger
|
Medical University, Innsbruck, Austria
|
mAbs to afamin and apolipoprotein A-IV
|
| 3 |
Nikolaus Franke |
Vienna University of Economics and Business, Vienna, Austria
|
Business planning
|
| 4 |
Juergen Haas |
Max von Pettenkofer Institute, LMU, Munich, Germany |
Development of mAbs to entire VZV proteome / development of recombinant fusion proteins |
| 5 |
Hartmut Hengel |
Heinrich-Heine University, Duesseldorf, Germany |
Immunobiology of CMV infection |
| 6 |
Ulrich Koszinowski |
Max von Pettenkofer Institute, LMU, Munich, Germany |
Characterization of structural CMV proteins and viral immunoevasins |
| 7 |
Ofer Mandelboim |
The Hebrew University Jerusalem, Israel |
Development of mAbs to cell surface markers on mouse and human NK cells |
| 8 |
David Margulies |
Laboratory of Immunology, NIAID, Maryland, USA |
Generation of mAbs to viral and cellular proteins |
| 9 |
Martin Messerle |
Medical School, Hannover, Germany |
Generation of mAbs to viral and cellular proteins |
| 10 |
Helmut E. Meyer |
Ruhr-Universität Bochum, Medizinisches Proteom-Center, Germany
|
Development of mAbs to human tumor markers |
| 11 |
Joanne Trgovcich |
Ohio State University, Columbus, USA |
Transcriptomic of mouse cytomegalovirus |
| 12 |
Alberto Visioli |
StemGen, Milan, Italy |
Development of mAbs to neuro-stem cells |
| 13 |
Sebastian Voigt |
Robert Koch-Institute, Berlin, Germany |
Development of mAbs against viral chemokines and cytokines |
| 14 |
Oliver Vugrek |
The Rudjer Boskovic Institute, Zagreb, Croatia |
Development of mAbs against SAHH protein |
